In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three ... profile in the oral GLP-1 space,” he said.

Lilly's R&D pipeline reveals that mazdutide is in phase 2 outside China. Meanwhile, other companies looking at combined GLP-1/glucagon agonists include Boehringer Ingelheim and Zealand Pharma ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. “HM17321 is the novel concept of obesity drug ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both ... It's also important to remember that ...

Q3 2024 Earnings Call Transcript November 8, 2024 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...